Jul 30, 2019
Gilead Raday,
COO, Redhill Biopharma, a specialty biopharmaceutical company
primarily focused on gastrointestinal (GI) diseases talks about the
growing problem of antibiotic resistance and the challenges this
presents treating H. pylori infections, which affects
about half of the global population. Redhill is working to
bring Talicia, a new treatment for H. pylori to market
potentially this year giving patients a new effective option for
H. pylori infection.
#RDHL $RDHL #Hpylori #IBD #GI
@RedHillBio